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ABSTRACT 
 
 
Novel mechanisms responsible for controlling glucose-induced 
insulin secretion in pancreatic beta-cells 
 
 
Glucose homeostasis is mainly regulated by the pancreatic hormone 
insulin. Pancreatic beta cells secrete insulin in response to changes in 
glucose concentrations through a complex and finely regulated 
mechanism. A large number of genetic alterations may affect the 
response of beta cells to glucose contributing to the onset of type 2 
Diabetes. Our group has identified a gene overexpressed in type 2 
diebetic individuals, ped/pea-15. A transgenic mouse model (Tgped/pea-15) 
ubiquitously overexpressing ped/pea-15 has been recently developed. 
Further studies have shown that Tgped/pea-15 displayed insulin resistance. 
I sought to analyze the role of ped/pea-15 in glucose-induced insulin 
secretion. Studies in vivo showed that Tgped/pea-15 mice have a 70% 
reduction of the first and second phase of insulin secretory response to 
glucose, in addition to fasting iperinsulinemia. Furthermore, Real Time 
PCR experiments performed on isolated islets from Tgped/pea-15 have 
shown that insulin secretion impairment is associated to a reduction of 
the expression of genes essential for insulin secretion: Sur1, Kir6.2 and 
HNF3β, by  30, 40 and 45% respectively. To investigate the molecular 
mechanisms underlying this alteration, a model of beta-cells stably 
overexpressing PED/PEA-15, MINped/pea-15 was generated. In these cells 
the lack of glucose-induced activation of the  Protein kinase C zeta 
(PKCζ) is responsible for the reduced expression of Sur1, Kir6.2 e 
HNF3β. Overexpression of PKCζ in MINped/pea-15, indeed, restored 
glucose-induced insulin secretion and  the expression of Sur1, Kir6.2 e 
HNF3β. Thus, PED/PEA-15 impairs glucose-induced insulin secretion by 
controlling the expression of the ATP-sensitive potassium channels in 
the beta-cell. 
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BACKGROUND 
 
 
§ 1.0 GLUCOSE HOMEOSTASIS 
Glucose homeostasis depends on its hepatic production and its 
utilization by insulin-dependent tissues such as adipose and muscle 
tissues. After a meal, glucose is absorbed into the hepatic portal vein, 
increasing the blood glucose concentration. This situation is detected by 
the pancreas, which secretes insulin from its beta-cells. Insulin causes 
glucose to be taken up by muscle, adipose tissues and the liver and 
converted into glycogen, reducing blood glucose, and in turn, causing 
the pancreas to stop secreting insulin (Pontieri 1996) (fig.1).  
 
                           
Figure 1. Glucose Homeostasis 
 
 
 
§ 1.1 PANCREATIC BETA-CELLS 
Beta-cells represent the 70-80% of the Langherans islets of the 
pancreas and occupy a central position in them (Orci and Unger 1975) 
(fig.2).The mammalian beta-cells synthesize, store, and secrete insulin 
in quantities that are matched to the physiological demands of the 
organism. To achieve this task, beta-cells are regulated both acutely 
and chronically by the extracellular glucose concentration (Schuit et al 
2002). Fundamental property of beta-cells is, indeed, their capacity to 
secrete insulin in response to changes in glucose concentrations 
(Newgard et al. 2002) . Insulin concentrations are normally determined 
by a feed-back control system that is responsive to the prevailing level 
of plasma glucose (Polonsky and O’Meara 2001). The overall sensitivity 
of the pancreatic beta-cells to glucose is determined by the sensitivity of 
peripheral tissues to the action of insulin with insulin-resistant subjects 
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having higher insulin levels and insulin secretion rates than insulin-
sensitive subjects (Bell and Polonsky 2001).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Representation of Langherans islets structure: alpha-cells are in peripheral 
position and beta-cells are in the centre (see also publication n°3 appended). 
 
 
 
§ 1.2 INSULIN 
Insulin is a quite small protein, having a molecular weight of about 6000 
Daltons. It is composed of two chains (A and B) held together by 
disulfide bonds. Insulin is synthesized in significant quantities only in β-
cells of the pancreas.  The insulin mRNA is translated as a single chain 
precursor called preproinsulin and removal of its signal peptide during 
cotraslational insertion into the endoplasmic reticulum generates 
proinsulin. Proinsulin consists of three domains: an amino-terminal B 
chain, a carboxy-terminal A chain and a connecting peptide known as 
the C peptide.  Within the endoplasmic reticulum, proinsulin is exposed 
to several specific endopeptidases which excise the C peptide, thereby 
generating the mature form of insulin. Insulin and free C peptide are 
packaged in the Golgi into secretory granules which accumulate in the 
cytoplasm (fig.3). When the beta-cell is appropriately stimulated, insulin 
is secreted from the cell by exocytosis and diffuses into islet capillary 
blood.  C peptide is also secreted into blood, but has no known 
biological activity (Bowen 1999). 
   
                                                                                                                                                 
α-cells β-cells
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Figure 3. Biosynthesis of insulin. 
 
 
 
§ 2.0 GLUCOSE-INDUCED INSULIN SECRETION 
Normal insulin secretion shows a rapid response to glucose and a 
complex pulsatile profile. The increase in insulin secretion that occurs 
after the intravenous administration of glucose is virtually 
instantaneous; even after oral glucose ingestion, increases in insulin 
secretion occur within minutes. The temporal profile of insulin secretion 
consists of small-amplitude pulses of insulin occurring every 5-10 
minutes, superimposed on slower, larger-amplitude oscillations that 
occur within 1 hour (Bell and Polonsky 2001). 
Glucose-induced insulin secretion is a complex mechanism made up of 
differents steps. Glucose enters the beta-cells by facilitated diffusion; a 
rise in extracellular glucose concentration increases its phosphorylation 
to glucose-6-phosphate by glucokinase, the rate-limiting enzyme for 
glucose metabolism in the beta-cells. Glucose phosphorylation by 
glucokinase determines the rate of glycolysis and the rate of pyruvate 
generation (Newgard and McGarry 1995, Matschinsky 1996). Thus, the 
rate of glycolysis will increase with increasing blood glucose levels. In β-
cells, pyruvate is the main product of glycolysis (Ishihara et al. 1999) 
and, compared to other cell types, an unusually high proportion of 
glucose-derived pyruvate enters the mitochondrial tricarboxylic acid 
cycle (Newgard and McGarry 1995) (fig.4A). Subsequent oxidative 
metabolism generates the trigger for insulin secretion (Wollheim 2000). 
Electron transfer from the tricarboxylic acid cycle to the respiratory 
chain by NADH and reduced flavin adenine dinucleotide (FADH2) 
initiates the production of ATP, which is delivered to the cytosol (fig.4B). 
Here the rise of the ATP-to-ADP ratio causes a reduction in plasma 
membrane K+ conductance, resulting in depolarization of the membrane 
(Rorsman 1997). Hence voltage-sensitive Ca2+ channels, similar to 
those expressed in other excitable cells, are opened (fig.4C). This is the 
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critical step by which glucose stimulates insulin secretion, as the 
increase in cytosolic Ca2+ is the main trigger for exocytosis (Rorsman 
1997, Lang 1999) (fig.4D).  
Insulin is also secreted in response to amino acids and fatty acids and 
the magnitude of this response is modulated by a variety of neural (for 
example, sympathetic and parasympathetic autonomic tone) and 
hormonal factors (for example, glucagons, glucagons-like peptide 1, 
gastric inhibitory polypeptide and somatostatin). Glucose, however, is 
the overriding influence (Bell and Polonsky 2001). 
Other inductors of insulin secretion are sulfonylureas. Their principal 
target is the ATP-sensitive potassium (KATP) channel, which plays a 
major role in controlling the beta-cell membrane potential. Inhibition of 
KATP channels by glucose or sulfonylurea, that binds to the Sur1 
subunit, causes depolarization of the  beta-cell membrane; in turn, this 
triggers the opening of voltage-gated Ca2+ channels, eliciting Ca2+ influx 
and a rise in intracellular Ca2+ which stimulates the exocytosis of 
insulin-containing secretory granules (Ashcroft et al. 1989). 
 
                                                         
 
            
                                                              
                                                         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Glucose-induced insulin secretion. 
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§ 2.1 REGULATION OF INSULIN SECRETION: ATP-sensitive 
potassium (KATP) channels 
The KATP channel is a hetero-octameric complex of two different types 
of protein subunits: an inwardly rectifying K+ channel, Kir 6.x, and a 
sulfonylurea receptor, Sur (Ashcroft and Griblle 1999, Aguilar-Bryan 
and Bryan 1999). Kir6.x belongs to the family of inwardly rectifying K+ 
(Kir) channels and assembles as a tetramer to form the channel pore. 
Binding of ATP to the intracellular domains of this subunit produces 
channel inhibition (Tucker et al. 1997). Sur is a member of the ABC 
transporter family, with 17 transmembrane helices, arranged as one 
group of 5 transmembrane helices, and two repeats each of 6 
transmembrane helices followed by a large cytosolic loop containing 
consensus sequences for nucleotide binding and hydrolysis (fig.5). 
Interaction of Mg nucleotides with the nucleotide binding domains 
mediates activation of the KATP channel (Nichols et al. 1996, Gribble et 
al 1998, Gribble et al 1997, Shyng et al. 1997). SUR also endows Kir6.2 
with sensitivity to certains drugs, such as the inhibitory sulfonyureas 
and the stimulatory K+ channel openers (Ashcroft and Gribble 1999, 
Aguilar Bryan  and Bryan 1999). More than one isoform exists for both 
Kir6.x (Kir 6.1, Kir 6.2) and SUR (SUR1, SUR2A, SUR2B).  
 
 
 
                                      
                      
                   
Figure 5. ATP-sensitive potassium (KATP) channels. 
 
 
In most tissues, Kir 6.2 serves as the pore forming subunit, but it 
associates with different SUR subunits; for example, it associates with 
SUR1 in the pancreas and brain, with SUR2A in heart and skeletal 
muscle, with SUR2B in brain  and smooth muscle (Aguilar Bryan et al 
1995, Inagaki et al 1996, Isomoto et al 1996). In vascular smooth 
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muscle, the KATP channel is composed of Kir6.1 in association with 
SUR2B (fig.6). Variation in the subunit composition of the KATP channel 
accounts for the different metabolic and drug sensitivities of KATP 
channels in different cells. Inhibitor of KATP channel activity fall into two 
groups: those that interact with Kir6.2 and those that interact with SUR. 
Imidazolines  ( phentolamine, cibenzoline) and antimalarials (quinine, 
mefloquine) block KATP channels by binding to Kir6.2 (Mukai et al. 1998, 
Proks and Ashcroft 1997, Gribble and Ashcroft 1999). In contrast, 
sulfoniylureas (tolbutamide, glicazide, glimeripide), and benzamino 
derivates (meglitinide) close KATP channels by binding with high affinity 
to SUR (Gribble and Ashcroft 1999, Gribble et al. 1997, Gribble et al. 
1998). All drugs that block KATP channels stimulate insulin secretion, but 
only those that interact with SUR subunit are used therapeutically. 
 
 
 
                     
 
Figure 6. Isoforms of the ATP-sensitive potassium (KATP) channels. 
 
 
 
§ 2.2 REGULATION OF INSULIN SECRETION: The role of Protein 
Kinase C 
The Protein kinase C (PKC) family can be divided in three subgroups 
based on cofactors requirements: classical PKCs (α, β, and γ), which 
are dependent on Ca2+ and diacylglycerol (DAG) for activity; novel 
PKCs (δ, ε, η, and θ), which are activated by DAG; and atypical PKCs 
(ζ, λ, and ι), which are not dependent on Ca2+ and are not stimulated by 
DAG (Hug and Sarre 1993) (Table1). PKCs play an important role in 
controlling a great number of  cellular functions among which insulin 
secretion. The role of classical PKCs as mediators of glucose-induced 
insulin secretion has been a subject of controversy, but it was 
demonstrated that glucose induces PKCα translocation in beta cells 
and that inhibition of PKCα blocks its translocation and the secretory 
response of beta-cells (Ganesan et al. 1990, Ganesan et al. 1992). 
Novel PKCs, in particular PKCε, play a role in cholinergic potentiation of 
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insulin secretion (Ishikawa et al. 2005) Atypical PKC isoforms are 
expressed in pancreatic beta-cells (Selbie et al. 1993) and play a role in 
the regulation of beta-cell growth and insulin secretion, as suggested by 
several reports on the role of atypical PKCs in insulin secretion 
(Furukawa et al. 1999, Harris et al. 1996), insulin synthesis (Furukawa 
et al. 1999, Harris et al. 1996), and cell proliferation (Buteau et al. 2001) 
in pancreatic beta-cells. PKCζ and PKCλ have been reported to control 
the function of a number of transcription factors (Furukawa N et al. 
1999, Matsumoto M et al. 2003, Hashimoto N et al. 2005). PKCλ has 
recently been shown to play a major role in regulating glucose-induced 
insulin secretion through the by modulating the expression of genes 
involved in this process (Hashimoto et al. 2005). Islets isolated from 
mice that lack the lambda isoform of PKC in pancreatic beta-cells show 
an impaired insulin secretion in response to high concentrations of 
glucose whereas the basal rate of insulin release is increased. The 
results indicate that PKCλ regulates glucose-induced insulin secretion 
by modulating the expression of genes important for beta cell function 
such as Glut2, HNF3β, Sur1, Kir6.2, Hexokinase 1 and Hexokinase 2 
(Hashimoto et al. 2005). 
 
CLASSICAL NOVEL ATYPICAL 
dependent on Ca2+ 
and diacylglycerol 
(DAG) 
dependent on 
diacylglycerol (DAG) 
not dependent 
on Ca2+ and 
diacylglycerol 
(DAG) 
   
α δ ζ 
β1 η λ 
β2 ε ι 
γ θ  
   
 
   Table 1. Classification of PKCs. 
 
 
 
§ 3.0 GENETIC ALTERATION IN INSULIN SECRETION 
Alteration of genes involved in insulin secretion may cause several 
disorders. Maturity-onset diabetes of the young (MODY) is a clinically 
heterogeneous group of disorders characterized by non-ketotic diabetes 
mellitus, an autosomal dominant mode of inheritance, onset usually 
before 25 years of age and frequently in childhood or adolescence, and 
a primary defect in pancreatic beta-cell function (Fajans et al. 2001, 
Owen and Hattersley 2001). MODY can result from mutation in any of 
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at least six different genes that encode the glycolytic enzyme 
glucokinase and five transcription factors: hepatocyte nuclear factor 
HNF-4α, HNF-1α, HNF-1β, insulin promoter factor-1 (IPF-1) and 
neurogenic differentiation 1/ beta-cell E-box transactivator2 
(NeuroD1/BETA2). This all are expressed in pancreatic β-cell and their 
mutations lead to beta-cell dysfunction and diabetes mellitus in 
heterozygous state. 
Glucokinase is expressed at high levels in the pancreatic β-cells and in 
the liver. Heterozygous mutations leading to partial deficiency of 
glucokinase are associated with MODY (Fajans et al. 2001, Owen and 
Hattersley 2001). The transcription factors HNF-1α, HNF-1β and HNF-
4α are involved in the tissue-specific regulation of gene expression in 
pancreatic beta-cells and other tissues (Cereghini 1996, Ryffel 2001). 
They belong to a network of transcription factors that controls gene 
expression during embryonic development and in the adult tissue in 
which they are co-expressed. In the pancreatic beta-cells, they regulate 
the expression of insulin as well as proteins involved in glucose 
transport, glycolysis and mitochondrial methabolism, all of which are 
important in the regulation of insulin secretion (Ryffel 2001, Emens et 
al.1992, Okita  et al. 1999, Wang et al. 2000, Wang et al. 2000, Shih et 
al. 2001). Mutations in these genes produce defects in insulin secretory 
responses to a variety of factors, in particular glucose, which are 
present before the onset of hyperglycemia (Fajans et al. 2001, Owen 
and Hattersley 2001). IPF-1 is a homeodomain-containing transcription 
factor involved in pancreatic development (Jonsson et al. 1994, Edlun 
1998, Stoffers et al.1997), transcriptional regulation of a number of β-
cell genes including insulin, glucokinase, islet amyloid polypeptide and 
glucose transporter 2 (GLUT-2) (Edlun 1998), and mediation of 
glucose-stimulated insulin gene transcription (Marshak et al. 1996). 
Mutations in the heterozygous state are associated with MODY 
(Stoffers et al.1997) whereas mouse and human homozygotes fail to 
develop the pancreas and suffer congenital diabetes mellitus (Stoffers 
et al.1997). IPF-1 mutation have also been discovered in a small 
fraction of patients with typical adult-onset type 2 diabetes (Macfarlane 
et al. 1999, Hani et al. 1999). Subjects with heterozygous mutation in 
IPF-1 featured reduced insulin secretory responses to glucose and 
glucagons-like-pepide-1, consistent with an effect in the signalling 
pathways that regulate secretion in the beta-cell and/or defect in β-cell 
mass (Cloquet et al. 2000). The transcription factor NeuroD1/BETA2 is 
involved in the regulation of transcription of the insulin gene and is 
required for normal pancreatic islet development (Chu et al. 2001). 
Mutations in NeuroD1 are a rare cause of MODY and result in reduced 
serum insulin concentrations (Malecki et al. 1999), either due to a 
signalling defect in the beta-cell, or to a reduction in beta-cell mass, or 
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both. Mutations in other beta-cell transcription factors may also 
contribute to the development of MODY or a MODY-like disorder. A 
nonsense mutation has been found in the LIM-homeodomain 
transcription factor islet-1 in a Japanese family (Shimomura et al. 2000). 
This mutation leads to a decreased activity and thus may be the cause 
of diabetes in this family. In addition to mutations in the nuclear 
genome, abnormal mitochondrial function resulting from mutations in 
the mithocondrial genome can lead to diabetes (Maassen et al. 1996). 
The most common diabetes-associated mutations is an A-to-G 
transition in the mitochondrial tRNAleu (UUR) gene at base pair 3,243. 
This results in defects in insulin secretion including failure of glucose to 
prime the insulin secretory response and abnormal insulin secretory 
oscillations (Velho et al. 1996). Mice with beta-cell specific disruption of 
mithocondria develop diabetes as a result of reduced beta-cell stimulus-
secretion coupling, followed by reduction in beta-cell mass (Silva et al. 
2000). 
 
 
 
§ 3.1 TYPE 2 DIABETES: GENETIC ALTERATION IN BETA-CELL 
DYSFUNCTION 
Type 2 diabetes is made up of different forms each of which is 
characterized by variable degree of insulin resistance and beta-cell 
dysfunction, and which together lead to hyperglycaemia (American 
Diabetes Association 2001). At each end of this spectrum are single-
gene disorders that affect the ability of the pancreatic beta-cell to 
secrete insulin (Fajans et al. 2001, Owen and Hattersley 2001) or the 
ability of muscle, fat and liver cells to respond to insulin (Taylor and 
Arioglu 1999, Barroso et al. 1999). 
In type 2 diabetes, more moderate abnormalities of insulin secretion are 
present that cause glucose intolerance only in the presence of insulin-
resistance. The genetic basis of beta-cell dysfunction in this form of 
diabetes is more complex, involving both multiple interacting genes and 
environmental factors, which determine whether and when diabetes will 
develop and at what age. Several genes involved in type 2 diabetes 
have been identified and their alterations has been characterized. A 
common amino-acid polymorphism (Pro12Ala) in peroxisome 
proliferators-activated receptor-γ (PPARγ) has been associated with 
type 2 diabetes (Altshuler et al. 2000). Patients homozygous for the 
Pro12 allele are more insulin resistant than those having one Ala12 
allele and have a 1,25-fold increased risk of developing diabetes (Luan 
et al. 2001). The expression of   PPARγ in insulin-responsive tissues (fat 
and muscle) (Olefsky 2000) and pancreatic beta-cells (Kulkarni et al. 
1999)  provides a link between insulin resistance and insulin secretion. 
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Genetic variation in the gene encoding calpain-10, a ubiquitously 
expressed cysteine 
protease, has also been associated with type 2 diabetes, increasing the 
risk as much as 3-fold (Horikawa et al 2000) by altering both the normal 
function of the beta-cells and insulin action in muscle and fat. Recently 
it has been discovered that IRS1 KO-/- mice are insulin resistant but 
they do not become diabetic probably because of a beta-cell’s 
compensation (Cavaghan et al. 2000). By contrast, IRS2 KO-/- mice 
show an alteration in insulin-secretion in addition to pheripheric insulin 
resistance and they develop diabetes (Cavaghan et al. 2000). 
 
 
 
 
 
Figure 7. Pathogenesis of Type 2 Diabetes. 
 
 
 
§ 4.0 PED/PEA-15 protein 
PED/PEA-15 (Phoshoprotein Enriched in Diabetes/ Phosphoprotein 
Enriched in Astrocytes) is a small scaffold multifunctional protein widely 
expressed in different tissues and highly conserved among mammals, 
whose gene maps on human chromosome 1q21-22 (Condorelli et al 
1998). PED/PEA-15 is characterized by a nuclear export sequence 
(NES) and a Death Effector Domain (DED) at the N-terminus side and 
two different sites of phosphorylation at the C-terminus side: the serine 
104 phosphorylated by PKC and the serine 116 phosphorylated by 
AKT/PKB. (fig.8) 
Several studies in cultured cells and in rodent tissues have revealed 
that PED/PEA-15 regulates multiple cellular functions by binding 
components of major intracellular transduction pathways (Zhang 
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2000,Formstecher et al. 2001, Trencia et al 2003, Vaidyanathan et al. 
2003, Vigliotta et al. 2004 see also publication n°3 appended,). These 
include ERK1/2, Akt, RSK2 and a number of molecules conveying 
apoptotic signals to the nucleus (Formstecher et al. 2001, Trencia et al 
2003, Vaidyanathan et al. 2003). PED/PEA-15 controls mitogenic 
signalling by binding extracellular signal-regulated kinases and 
anchoring them to the cytoplasm (Formstecher et al. 2001). It also 
inhibits several apoptotic pathways through a number of different 
mechanisms and plays an important role in tumor development and 
sensitivity to antineoplastic agents (Condorelli et al. 2002, Condorelli et 
al. 1999, Estelles et al. 1999, Hao et al. 2001, Trencia et al. 2003, Xiao 
et al. 2002, Formisano et al. 2005). PED/PEA-15 also binds to and 
increase the stability of phospholipase D, enhancing its activity and 
controlling important mechanisms in cell metabolism (Zhang et al. 
2000).   
 
 
 
 
 
      
 
 
 
 
 
 
 
 
 
 
Figure 8. Structure of PED/PEA-15 protein. 
 
 
 
§ 4.1 PED/PEA-15 AND GLUCOSE HOMEOSTASIS 
Gene profile studies showed that overexpression of the ped/pea-15 
gene is a common defect in individuals with Type 2 diabetes as well as 
in non-diabetic individuals at high risk to develop diabetes (as the first-
degree relatives of diabetic subjects) (Condorelli et al. 1998, Valentino 
et al. 2006). To investigate the relevance of ped/pea-15 overexpression 
to glucose tolerance, transgenic mice ubiquitously overexpressing 
human ped/pea-15 were generated (Tgped/pea-15). These mice exhibited 
mildly elevated random-fed blood glucose levels and decreased glucose 
tolerance (fig. 9A). In cultured muscle and adipose cells and in 
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peripheral tissues from Tgped/pea-15, high levels of PED/PEA-15 impair 
insulin-stimulated GLUT4 translocation and glucose transport, 
suggesting that PED/PEA-15 overexpression may contribute to insulin 
resistance in Type 2 diabetes (Condorelli et al. 2001, Vigliotta et al. 
2004 see also publication n°3 appended). In transgenic mice, indeed, 
insulin administration reduced glucose levels by only 35% after 45 min, 
compared to 70% in control mice (fig 9B). In vivo, insulin-stimulated 
glucose uptake was decreased by almost 50% in fat and muscle tissues 
from Tgped/pea-15 accompanied by a constitutively  activated protein 
kinase Cα  and lack of protein kinase Cζ induction by insulin. These 
changes persisted in isolated adipocytes from the transgenic mice and 
were rescued by the protein kinase C inhibitor bisindolylmaleimide.  
 
A.                                                          B. 
 
 
 
 
 
Figure 9. A. Glucose Tolerance Test and B. Insulin Tolerance test in Tgped/pea-15 (see 
also publication n°3 appended). 
 
 
This point has been further confirmed by other studies where PED/PEA-
15-induced insulin resistance is accompanied by PLD-dependent 
activation of PKCα (Vigliotta et al. 2004 see also publication n°3 
appended), leading to the failure of PKCζ activation by insulin 
(Condorelli et al. 2001,  et al. 2004 see also publication n°3 appended) 
(fig.10).  
 
                                  
 
Figure 10. Proposed mechanism of PED action on insulin-stimulated glucose 
transport (see also publication n°3 appended). 
Tgped/pea-15  
 C1 
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Rescue of PKCζ activity in cells overexpressing PED/PEA-15 restores 
normal sensitivity to insulin of the glucose transport machinery 
(Condorelli et al. 2001). Thus, in muscle and adipose cells, PED/PEA-
15 generates resistance to insulin action on glucose disposal by 
impairing normal regulation of PKCζ (Condorelli et al. 2001). 
Furthermore, more recent studies revealed that, in first-degree relatives 
of Type 2 diabetic subjects, PED/PEA-15 levels negatively correlate 
with insulin sensitivity (Valentino et al. 2006). 
Other studies (Vigliotta et al. 2004 see also publication n°3 appended) 
have demonstrated that after a treatment with a 60% fat diet 
nontransgenic mice showed little change in glucose tolerance, while 
Tgped/pea-15 developed diabetes (fig.11). This additional finding suggests 
an important interaction of environmental modifiers with ped/pea-15 
gene function, leading to a further derangement in glucose tolerance. 
Based on insulin tolerance tests, Tgped/pea-15 developed only a further 
20% increase in insulin resistance after the high-fat diet while 
nontransgenic mice undergo a 60% reduction in their sensitivity to 
insulin  becoming as insulin resistant as their transgenic littermates. We 
have therefore hypothesized that resistance to insulin action alone is 
not sufficient to cause the alteration in glucose tolerance of the Tgped/pea-
15. To verify this hypothesis we started to study glucose-induced insulin 
secretion.  
 
 
 
                               
Figure 11. Effect of high-fat feeding on glucose tolerance in Tgped/pea-15. (see also 
publication n°3 appended). 
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AIM OF THE STUDY 
 
 
Ped/Pea-15, a gene overexpressed in type 2 diabetics, causes 
peripheral insulin-resistance and reduces glucose tolerance in 
transgenic mice overexpressing the protein. Furthermore, these mice 
were  hyperinsulinemic in fasted conditions. Treatment with a 60% fat 
diet led Tgped/pea-15 to develop diabetes. Since insulin resistance was 
only slightly worse by the high fat diet in Tgped/pea-15, it was hypothesized 
that resistance to insulin action alone is not sufficient to cause the 
alteration in glucose tolerance of the Tgped/pea-15.  
To this aim I sought to analyze the effect of PED/PEA-15 on glucose-
induced insulin secretion and to investigate the molecular mechanism 
underlying this process.  
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MATERIALS AND METHODS 
 
 
 
MEASUREMENT OF INSULIN SECRETION IN VIVO. 
For analysing insulin secretion, mice were fasted overnight and then 
injected with glucose (3 g.kg of body weight-1) intraperitoneally. Venous 
blood was drawn at 0, 3, 10 and 30 min after glucose injection by retro-
orbital bleeding, and plasma insulin concentrations were measured by 
radioimmunoassay (RIA) (Kulkarni et al. 1999) with rat insulin as 
standard (Insulin Rat RIA KIT, LINCO Research, MO).  
 
 
IMMUNOHISTOCHEMICAL ANALYSIS.  
Pancreas from transgenic and control animals were fixed in 4% 
paraformaldehyde–0.1 M sodium phosphate buffer at 4°C overnight and 
placed in 30% sucrose at 4°C overnight. After being embedded in 
Tissue-Tek OTC compound and frozen at < 20°C, tissue sections were 
prepared. Immunohistochemical analysis was carried out with the H38 
rabbit insulin antibody (Santa Cruz Biotechnology, Inc.; 1:200 dilution), 
the N-17 goat glucagon antibody (Santa Cruz Biotechnology, Inc.; 1:200 
dilution), or PED/PEA-15 antiserum (Condorelli 1998) (1:20,000 
dilution). Incubation with the primary antibody was followed by 
incubation with biotinylated anti-rabbit or anti-goat immunoglobulin G 
and peroxidase-labeled streptavidin. Analysis of serial consecutive islet 
sections stained with either insulin or the PED/PEA-15 antibodies was 
used to confirm ped/pea-15 expression in insulin-immunopositive beta 
cells. 
 
 
 
ISLET ISOLATION, EX VIVO INSULIN SECRETION ASSESSMENT 
AND ESTIMATION PANCREATIC INSULIN CONTENT. 
Islets were isolated from 6-month-old mice by collagenase digestion 
and subsequent centrifugation on a Histopaque (Sigma-Aldrich, MO) 
gradient as previously described (Kitamura et al. 2001). For assaying of 
insulin release, 20 islets were manually selected, cultured for 24h, 
incubated in Krebs-Ringer solution (120 mM NaCl, 1.2 mM MgSO4, 5 
mM KCl, 10 mM NaHCO3, 1,3 mM CaCl2, 1,2 mM KH2PO4) for 30 min, 
and then stimulated at 37°C with various concentrations of either 
glucose for 1 hour, KCl for 30 minutes, or glyburide (Sigma-Aldrich, 
MO) for 1 hour. The islets were subsequently collected by 
20 
centrifugation, and supernatants were assayed for insulin content by 
RIA as described above. For measuring total pancreatic insulin, 
pancreases were solubilized in acid-ethanol solution (75% ethanol, 
1.5% HCl) overnight at 4°C and lysates centrifuged for 15 min. at 800g. 
Pancreatic insulin was measured in the supernatants by RIA. 
 
 
 
REAL-TIME RT-PCR ANALYSIS.  
Total cellular RNA was isolated from pancreatic islets and cells by the 
use of RNeasy kit (QIAGEN Sciences, Germany), according to the 
manufacturer’s instructions. For Real-time RT-PCR analysis, 1 μg of 
islet or cell RNA was reverse-trascribed using Superscript II Reverse 
Trascriptase (Invitrogen, CA). PCR reaction mixes were analyzed using 
SYBR Green mix (Invitrogen, CA). Reactions were performed using 
Platinum SYBR Green qPCR Super-UDG using an iCycler IQ multicolor 
Real Time PCR Detection System (Biorad, CA). All reactions were 
performed in triplicate and β-actin was used as an internal standard.  
 
 
 
CELL CULTURE PROCEDURES AND TRANSFECTION.  
MIN-6 cells were cultured in Dulbecco’s modified Eagle’s medium (Life 
Technologies, Germany) containing 25 mM glucose, 50 μM 2-
mercaptoethanol, and 10% fetal calf serum (Biochrom, Germany) at 
37°C in a 5% CO2 atmosphere as in (Miyazaki et al. 1990). 
Transfections of the Ped/pea-15 and PKCζ cDNAs were performed as 
described previously (Condorelli et al. 2001). 
 
 
 
WESTERN BLOT ANALYSIS.  
For these studies cells were solubilized in lysis buffer (50 mM HEPES, 
pH 7.5, 150 mM NaCl, 10 mM EDTA, 10 mM Na4P2O7, 2 mM Na3VO4, 
100 mM NaF, 10% glycerol, 1% Triton X-100, 1 mM PMSF, 10 mg/ml 
aprotinin) for 1 h at 4°C and lysates were centrifuged at 5,000g for 20 
min. Homogenates and cell lysates were subjected to sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) with 10% gels, 
as described by Laemmli 1970. Proteins separated on the gels were 
electroblotted on 0.45-mm Immobilon-P membranes (Millipore 
Corporation, MA) as previously described (Condorelli et al. 2001) and 
probed with antibodies to PED/PEA-15 (Condorelli et al. 1998), 
PKCζ (Santa Cruz Biotechnology, Inc., CA), or tubulin (Santa Cruz 
Biotechnology, Inc., CA). 
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PKC ASSAY.  
PKC activity was measured as previously described (Condorelli et al. 
2001). Briefly, for these assays, cells were solubilized in lysis buffer (50 
mmol/l HEPES, pH 7.5, 150 mmol/l NaCl, 10 mmol/l EDTA, 10 mmol/l 
Na4P2O7, 2 mmol/l Na3VO4, 100 mmol/l NaF, 10% glycerol, 1% Triton 
X-100, 1 mmol/l PMSF, 10 mg/ml aprotinin) for 1 h at 4°C. Lysates were 
centrifuged at 5,000g for 20 min and activity of the specific PKC 
isoforms was assayed after immunoprecipitation with specific antibodies 
PKCζ (Santa Cruz Biotechnology, Inc., CA) (Condorelli et al. 2001). 
Soluble pellets were supplemented with the lipid activators (10 mmol/l 
phorbol 12-myristate 13-acetate, 0.28 mg/ml phosphatidyl serine, and 4 
mg/ml dioleine, final concentrations) and phosphorylation reactions 
initiated by addition of the substrate solution (50 mmol/l Ac-MBP [4 –
14], 20 mmol/l ATP, 1 mmol/l CaCl2, 20 mmol/l MgCl2, 4 mmol/l Tris, pH 
7.5, and 10 μCi/ml [3,000 Ci/mmol] [γ-32P]ATP, final concentrations). 
The reaction mixtures were further incubated for 30 min at room 
temperature, rapidly cooled on ice, and spotted on phosphocellulose 
discs, according to the kit manufacturer’s instructions (Promega, Wi). 
Disc-bound radioactivity was quantitated by liquid scintillation counting.   
 
 
 
STATISTICAL PROCEDURES.  
Data were analysed with Statview software (Abacus-concepts) by one-
factor analysis of variance. P values of less than 0,05 were considered 
statistically significant.  
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RESULTS AND DISCUSSION 
 
 
 
To evaluate the role of PED/PEA-15 overexpression on glucose-
induced insulin secretion we started studing the in vivo glucose induced 
insulin secretion in ped/pea-15 transgenic mice (Tgped/pea-15 mice). Firstly 
we analyzed the expression of PED/PEA-15 in pancreatic sections of 
Tgped/pea-15 mice. Staining of pancreas sections with specific PED/PEA-
15 antibodies revealed a significant increase in the immunoreactivity of 
the islet cores, where beta-cells are localized, in Tgped/pea-15 mice 
compared to their relative wild-type littermates (C1) (Fig.12A). At 
variance, both insulin and glucagon immunoreactivities were 
comparable in Tgped/pea-15 mice and C1 mice. We next compared insulin 
secretion following a glucose load in Tgped/pea-15 and in C1 mice. In C1 
mice, a six fold increase in insulin secretion was observed 3 min after 
intraperitoneal glucose injection, and the levels remained higher than 
the baseline values for up to 30 min, indicating a second-phase 
response (Fig.12B). Based on insulin area under the curve quantitation, 
the acute first-phase of insulin secretory response to glucose was 
reduced by almost 70% in Tgped/pea-15 mice (p< 0.001). The second-
phase was also significantly impaired in Tgped/pea-15 mice compared to C1 
(p< 0.01).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
23 
 
A                   
 
 
 
 
 
 
B   
 
 
 
               
 
 
 
 
 
 
 
 
FIG.12. Insulin secretion in ped/pea-15 transgenic mice.  
A. Pancreas from ped/pea-15 transgenic mice (Tgped/pea-15 mice) and their 
nontransgenic littermates (C1) were fixed and embedded in Tissue-Tek OTC, and 
sections were prepared as described under Materials and Methods. 
Immunohistochemical analysis of the islets was carried out with PED/PEA-15, insulin, 
and glucagon antibodies as indicated. Anti-rabbit or anti-goat immunoglobulin G was 
used as the secondary antibody. Immunoreactivity was revealed by peroxidase-
labeled streptavidin. The microphotographs shown are representative of images 
obtained from eight transgenic (four male and four female) and seven nontransgenic 
mice (three male and four female). B. Tgped/pea-15 mice and C1 were subjected to 
intraperitoneal glucose loading, followed by determination of plasma insulin levels at 
the indicated times. Data points represent the mean ± standard deviation of 
determinations in 14 Tgped/pea-15  (seven female and seven male) and 16 C1 (eight 
female and eight male). 
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To test the hypothesis that overexpression of PED/PEA-15 in beta-cells 
is sufficient to impair hyperglycemia-induced insulin secretion, we 
isolated islets from Tgped/pea-15 and C1 mice pancreas. First we examined 
the expression of PED/PEA-15 by immunoblot analysis (Figure 13). The 
amount of PED/PEA-15 in islets of Tgped/pea-15 was increased by about 
3-4 folds (p<0,001) compared to that in islets of C1 mice (fig.13A). Then 
we measured insulin secretion in islets from Tgped/pea-15 mice and C1. 
Islets isolated from Tgped/pea-15 showed 3-fold increased insulin release 
when exposed to 2.8 mM glucose (p< 0.001) and no further release 
upon exposure to 16.7 mM glucose (fig.13B). At variance with glucose, 
exposure to the membrane depolarising agent potassium chloride (33 
mM) caused a comparable release of insulin by the Tgped/pea-15 mice and 
C1 islets. This last result indicates that the site of PED/PEA-15 action on 
glucose-induced secretion is upstream the membrane depolarization 
step. 
Total insulin content of pancreatic islets from Tgped/pea-15 mice was not 
increased compared with that in islets from C1 mice (Tgped/pea-
15=110±20pg/mg protein and C1=120±20pg/mg protein) and it may not 
account for the difference in basal insulin secretion. These findings led 
us to focus on the possibility that the overexpression of PED/PEA-15 
mainly impairs the glucose sensing rather than the insulin biosynthetic 
machinery of the beta-cell. 
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A                                
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Fig.13. PED/PEA-15 overexpression and insulin secretion in Tgped/pea-15  islets   
A. Islets were isolated and solubilized in lysis buffer as described under Materials and 
Methods and PED/PEA-15 expression was evaluated by immunoblot analysis.  
B. Islets were isolated from 6-month old mice from Tgped/pea-15 mice and C1 mice. Islets 
were incubated in KRB solution for 30 min and insulin release was determined upon 
exposure to the indicated concentrations of glucose or potassium chloride, 
respectively for 60 and 30 further min, as described under Materials and Methods. 
Bars represent the means ± SD of determinations 11 independent experiments in 
duplicate. Asterisks denote statistically significant differences (***, P < 0.001). 
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To gain further insight into the mechanisms leading to dysfunction of 
beta-cell overexpressing PED/PEA-15, we have profiled the expression 
of several genes relevant to the glucose sensory apparatus by real-time 
RT-PCR analysis of total RNA isolated from islets of Tgped/pea-15 mice 
(Figure 14). The amounts of mRNAs for the Sur1 subunit of the ATP-
sensitive K+ channel was significantly reduced by 30% in these islets 
compared with those in control mice (p<0.001). RNAs encoding the 
Kir6.2 potassium channel subunit and the Sur1/Kir6.2 upstream 
regulator Foxa2 were also reduced, respectively, by 40 and 45% in the 
islets from the Tgped/pea-15 mice (p<0.01) (fig.14A). Consistently, islets 
from Tgped/pea-15 mice exhibited no secretory response to the K+ channel 
locking agent gliburyde (fig.14B). At variance, the abundance of 
glucokinase, HK1, HK2, and GLUT2 mRNAs did not differ between 
Tgped/pea-15 and C1 mice. Thus, beta-cell expression profiling revealed 
that mRNA abundance of both the Kir6.2 and the Sur1 transcripts are 
significantly depressed by the overexpression of PED/PEA-15. 
PED/PEA-15 action on the Kir6.2 and the Sur1 genes represents a 
specific abnormality as other genes encoding key components of the 
glucose-sensitive insulin secretion machinery were unaffected by 
PED/PEA-15. Consistent with the functional consequence of this defect, 
the potassium channel locking agent glyburide showed impaired action 
on insulin secretion in PED/PEA-15 overexpressing islets.  Previous 
studies in mice evidenced that ablation of either the Sur1 or the Kir6.2 
genes results in a phenotype reminiscent of that characterizing the 
Tgped/pea-15 mice (Miki et al. 1998, Nenquin et al. 2004, Seghers et al. 
2000). Indeed, both the Sur1-/- and the Kir6.2-/- mice feature blunted 
insulin secretion response to sulfanylureas. The defective insulin 
response to the sulfanylurea glyburide seems even more pronounced in 
the Tgped/pea-15 mice as, in these animals, less than 40% decrease in 
Sur1 and Kir6.2 gene expression blocks glyburide action. At variance 
with the Sur1-/- and the Kir6.2-/- mice however, in the Tgped/pea-15 mice 
PED/PEA-15 simultaneously depresses the expression of both the Sur1 
and the Kir6.2 genes. The simultaneous impairment in their function 
may result in an additive effect on glyburide action. Similar to the 
Tgped/pea-15 mice, fasted Sur1-/- mice are more hyperinsulinemic than 
control animals due to persistent activation of voltage-gated calcium 
channels. Furthermore, both the Sur1-/- and the Kir6.2-/- mice feature 
impaired glucose tolerance and glucose-induced first and second phase 
insulin secretion. Thus, at least in part, the loss of potassium channels 
caused by beta-cell overexpression of PED/PEA-15 may account for 
the abnormalities in basal and glucose-stimulated insulin secretion and 
in glucose tolerance observed in the Tgped/pea-15 mice. 
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Fig.14. Gene expression profile in isolated islets from Tgped/pea-15 mice.  
A. The abundance of mRNAs for the indicated proteins was determined by real-time 
RT-PCR analysis of total RNA isolated from islets of Tgped/pea-15 mice and their non 
transgenic littermates (C1). All reactions were performed using beta-actin as internal 
standard as described under Materials and Methods. The mRNA levels in Tgped/pea-15 
mice islets are relative to those in C1. Each bar represents the mean ± SD of five 
independent experiments in each of whom reactions were performed in triplicate using 
the pooled total RNAs from 6 mice/genotype. B. Islets were isolated from 6-month 
Tgped/pea-15 mice and from C1. Islets were incubated in KRB solution for 30 min. and 
insulin release was determined after exposure to 10 μM glyburide for 60 further min, 
as described under Materials and Methods. Bars represent the means ± SD of data 
from 4 independent experiments each with at least 3 mice/group. Asterisks denote 
statistically significant differences (**, p < 0.01; ***, p < 0.001). 
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To elucidate the mechanism by which Ped/Pea-15 impairs the 
expression of Sur1, Kir6,2 and HNF3β (Foxa2) we generated MIN6 
beta-cell lines stably overexpressing PED/PEA-15 by 10-fold above 
endogenous levels (MIN-6ped/pea-15) (Fig.15A). We then compared insulin 
secretion in these cells and in cells expressing only endogenous 
PED/PEA-15, the MIN6 cells. MIN6 cells responded with about 4 folds 
(p< 0.001) induction in insulin secretion when subjected to physiological 
increases of glucose concentration in the medium (Fig.15B). In these 
same cells, the overexpression of PED/PEA-15 increased basal insulin 
secretion of about 2,5 folds (p< 0.001) and reduced glucose-induced 
insulin secretion of about 90%. Treatment with a specific antisense 
oligonucleotide effectively blocked PED/PEA-15 expression in MIN6 
and in MIN-6ped/pea-15 cells and almost completely rescued the abnormal 
insulin secretion in the MIN-6ped/pea-15 cells (Fig.15C) (p< 0.01). In 
addition, antisense transfection of MIN-6 control cells enhanced 
glucose-induced insulin secretion by about 2- fold (Fig.12D) (p< 0.01), 
indicating that this gene has a physiological role in controlling beta-cell 
secretion in response to glucose.  Gene expression profile show a close 
to 40% decrease in the abundance of the Sur1, Kir6.2 and Foxa2 
mRNAs (Fig.14E) in MIN-6ped/pea-15 cells compared to MIN-6 cells 
(p<0.001). At variance, the abundance of glucokinase, HK1, HK2, and 
GLUT2 mRNAs did not differ between MIN6 and MIN-6ped/pea-15 cells. 
Data obtained in MIN-6 cells further suggest an important role for 
ped/pea-15 in the regulation of both insulin secretion and gene 
expression. 
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Fig.15. Characterization of ped/pea-15-overexpressing MIN6 cells. A. MIN6 beta 
cells were stably transfected with ped/pea-15 cDNA and a clone overexpressing 
ped/pea-15 by 10-fold was selected MIN-6ped/pea-15. B.  Insulin release was assayed by 
radioimmunoassay in the culture medium of MIN-6 and of MIN-6ped/pea-15 cells upon 60 
min incubation with the indicated glucose concentrations. Bars represent mean values 
± SD from 6 independent experiments each in duplicate. Asterisks indicate statistically 
significant differences (***, P < 0.001). C and D. MIN-6 and MIN-6ped/pea-15 were 
transfected either with ped/pea-15 antisense (AS) or with scrambled (SC) 
oligonucleotides. Glucose-stimulated insulin secretion was assayed as outlined above. 
Bars represent values ± standard deviation of triplicate measurements in four 
independent experiments. Asterisks indicate statistically significant differences (***, P 
< 0.01). E. The abundance of mRNAs for the indicated proteins was determined by 
real-time RT-PCR analysis of total RNA isolated from MIN-6 and MIN-6ped/pea-15 cells. 
Bars represent the mRNA levels in the transfected cells and are relative to those in 
wild-type (control) cells. Data are expressed as means ± SD of triplicate reactions for 
total RNAs from each cell type in five independent experiments. Asterisks indicate 
statistically significant differences (***, p < 0.001). 
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Recent evidences in skeletal muscle and fat indicated that high cellular 
levels of PED/PEA-15 impair the function of the atypical PKC isoform 
PKC zeta (Vigliotta et al. 2004 see also publication n°3 appended, 
Zhang et al. 2000). In addition, the atypical PKC lambda has recently 
been shown to play a major role in regulating glucose-induced insulin 
secretion through the modulation of the expression of multiple genes in 
pancreatic beta-cells (Seghers et al. 2000). These include Sur1 and 
Kir6.2. In MIN-6, the effect of glucose on insulin release was paralleled 
by a 2-fold increase in immunoprecipitated PKC zeta activity (fig.16B), 
with no measurable change in its expression (fig.16A). Furthermore, the 
effect of glucose was almost completely abolished in Min-6ped/pea-15  
cells. These data could suggest an important role of atypical PKCs in 
regulating genes of the insulin secretion pathway. Down-regulation of 
PKC zeta observed in Min-6ped/pea-15 may cause impaired glucose-
induced insulin response in islets from Tgped/pea-15 mice by reducing Sur1 
and Kir6.2 gene expression 
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          B 
        
 
 
 
 
 
 
 
Fig.16. B. MIN-6 cells and MIN-6ped/pea-15 were exposed to 16.7 mM glucose for 60 min 
and then solubilized. Lysates were then precipitated with PKC zeta antibody and PKC 
activity was assayed in the precipitates as described under Materials and Methods. 
PKC zeta activity is expressed as fold-increase over basal activity (measured in the 
presence of 2.8 mM glucose). Bars represent the mean ± SD of data from 4 
independent experiments. Asterisks indicate statistically significant differences (*, P < 
0.05). A. For control, aliquots of the cell lysates were normalized for protein and 
directly blotted with PKC zeta antibodies. Blots were revealed by ECL and 
autoradiography. The blot shown in the inset is representative of those in the other 3 
experiments. 
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To further address this issue, we forced the expression of PKCζ in MIN-
6ped/pea-15 cells. As shown in Fig. 17A, overexpression of PKCζ to high 
levels largely rescued PKC activity in the PKCζ precipitates from 
glucose-exposed MIN-6 and MIN-6ped/pea-15 cells. Importantly, this 
rescue was accompanied  in MIN-6ped/pea-15 cells by recovery in Sur1, 
Kir6.2 and Foxa2 gene expression (Fig. 17B). In part, changes in insulin 
release caused by PED/PEA-15 were also reverted, determining 
recovery of glucose-induced insulin secretion (Fig. 17C). These data 
indicate that the changes in atypical PKC function caused by PED/PEA-
15 overexpression represent upstream abnormalities impairing the 
function of multiple genes involved in the regulation of insulin secretion 
by the beta-cell. PKCζ/λ have been reported to control the function of a 
number of transcription factors (Furukawa et al. 1999, Matsumoto et al. 
2003). Very recent data evidenced that, in PKC lambda null mice, the 
expression of the Foxa2 mRNA in addition to that of Sur1 and Kir6.2, 
was significantly reduced in pancreatic beta-cells (Hashimoto et al. 
2005). In addition, in pancreatic beta-cells, the expression of the Sur1 
and Kir6.2 genes is dependent on Foxa2 activity (Wang et al. 2002, Lee 
et al. 2002,  Sund et al. 2001). Similar to the PKCλ-/- mice, we now 
report that Foxa2 mRNA abundance is also reduced in islets from 
Tgped/pea-15 mice. Thus, impaired activity of atypical PKCs in beta-cells 
overexpressing PED/PEA-15 may prevent normal potassium channel 
generation and glucose-regulated insulin secretion by depressing 
Foxa2 expression. Supporting this conclusion, we evidenced that 
forcing the expression of PKCζ, in PED/PEA-15 overexpressing beta-
cells, rescued Foxa2 levels in addition to those of Kir6.2 and Sur1 and 
to glucose-induced insulin secretion.  
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Fig.17. Rescue of PKCzeta activity, gene expression profile and glucose-
stimulated insulin secretion in MINped/pea-15 cells. A. MIN-6 and MIN-6ped/pea-15 
cells were stably transfected with a PKCzeta cDNA, solubilized and lysates 
immunoprecipitated with a PKCζ antibody. PKCζ activity was assayed in the 
immunoprecipitates as described under Materials and Methods. For control, aliquots 
of the lysates were blotted with the PKCζ antibody and filters revealed by ECL and 
autoradiography. Bars represent the means ± SD of five independent experiments in 
duplicate. The autoradiograph shown in the inset is representative of blots from five 
experiments. B. The abundance of mRNAs for the indicated proteins was determined 
by real-time RT-PCR analysis of total RNA isolated from MIN-6 and MIN-6ped/pea-15 
cells. Bars represent the mRNA levels in the MIN-6ped/pea-15 cells and are relative to 
those in the untransfected cells (MIN-6). Data are expressed as means ± SD of 
triplicate reactions for total RNAs from each cell type in four independent experiments. 
C. The MIN-6 cells, either those transfected with the PKCζ cDNA and the 
untransfected cells, were exposed to 16.7 mM glucose for 60 min and insulin release 
in the culture medium was assayed by radioimmunoassay as described under 
Materials and Methods. Bars represent the means ± standard deviations of duplicate 
determinations in three independent experiments. Asterisks indicate statistically 
significant differences (*, p<0.05). 
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CONCLUSIONS 
 
Ped/pea-15, is a novel gene shown be overexpressed in type 2 
diabetics and involved in peripheral insulin resistance. In this thesis I 
have shown that, in addition to fasting iperinsulinemia, Tgped/pea-15 mice 
have a reduction of insulin secretory response to glucose due to the 
lack of glucose-induced activation of the Protein kinase C zeta (PKCζ). 
This alteration results in the downregulation of the expression of the two 
subunits of the ATP-dependent K+ channel Sur1 and Kir6.2 and their 
regulator Foxa2. In addition, the control of glucose-regulated insulin 
secretion appears to represent a physiological function of ped/pea-15 in 
beta cells. Indeed, transfection of a specific antisense oligonucleotide 
into MIN6 cells expressing only endogenous ped/pea-15 enhanced 
glucose-induced insulin secretion by almost twofold. Thus, the 
overexpression of PED/PEA-15 causes simultaneously insulin 
resistance and impaired insulin secretion. Under appropriate 
environmental conditions, ped/pea-15 overexpression leads to diabetes 
in mice, thus indicating that PED-PEA-15 could contribute to genetic 
susceptibility to type 2 diabetes in humans. Thus, decreasing ped/pea-
15 levels might be an innovative therapeutic approach for the treatment 
of type 2 diabetes. 
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